• +1(847) 967-6000
  • Resources
  • Blog
  • News
  • Events
  • Careers
ESTEVE CDMO Acquires Regis Technologies, expanding U.S. presence and capabilitiesESTEVE CDMO Acquires Regis Technologies, expanding U.S. presence and capabilitiesESTEVE CDMO Acquires Regis Technologies, expanding U.S. presence and capabilitiesESTEVE CDMO Acquires Regis Technologies, expanding U.S. presence and capabilities
  • About Us
    • About Regis
    • Our Team
    • Facility Tour
    • Manufacturing Facility Details
    • Our Distributors
  • Custom API
    • CUSTOM API DEVELOPMENT
      • Analytical Development
      • Process Chemistry
    • cGMP MANUFACTURING
      • CGMP Scale Up
      • Clinical Trial Material
      • Commercial API
      • Custom API Manufacturing
      • HPAPI Manufacturing
    • DEVELOPMENT AND MANUFACTURING SUPPORT
      • Fate and Purge
      • Impurity Services
      • IND Enabling Supply
      • Milling
      • Project Management
      • Quality Assurance
      • Quality Control
      • Solid State Chemistry
      • Stability Services
  • Chromatography Products
    • CHROMATOGRAPHY COLUMNS
      • Chiral HPLC & SFC Columns
      • Achiral HPLC & SFC Columns
      • Reversed-Phase HPLC Columns
      • Immobilized Artificial
        Membrane (IAM) Chromatography
      • Free Chiral Screening Service
    • SPECIALTY REAGENTS
      • Ion Pairing Reagents
      • Derivatizing Reagents
  • IMAGING REAGENTS
    • Coelenterazine
    • Luciferin
    • 4-Chloro-1-Naphthol
  • Contact Us
  • ABOUT US
    • About Regis
    • Our Team
    • Facility Tour
    • Manufacturing Facility Details
    • Our Distributors
  • CUSTOM API
    • CUSTOM API DEVELOPMENT
      • Analytical Development
      • Process Chemistry
    • cGMP MANUFACTURING
      • CGMP Scale Up
      • Clinical Trial Material
      • Commercial API
      • Custom API Manufacturing
      • HPAPI Manufacturing
    • DEVELOPMENT AND MANUFACTURING SUPPORT
      • Fate and Purge
      • Impurity Services
      • IND Enabling Supply
      • Milling
      • Project Management
      • Quality Assurance
      • Quality Control
      • Solid State Chemistry
      • Stability Services
  • CHROMATOGRAPHY PRODUCTS
    • Chromatography Columns
      • Chiral HPLC & SFC Columns
      • Achiral SFC Columns
      • Reversed-Phase HPLC Columns
      • Immobilized Artificial Membrane (IAM) Chromatography
    • Specialty Reagents
      • Ion Pairing Reagents
      • Derivatizing Reagents
  • IMAGING REAGENTS
    • Coelenterazine
    • Luciferin
  • CONTACT US
  • News
  • Blog
  • Resources
  • Events
  • Careers
0

ESTEVE CDMO Acquires Regis Technologies, expanding U.S. presence and capabilities

July 30, 2025
Esteve Advancing Health Together

This acquisition enables ESTEVE CDMO (Esteve Química) to expand its contract development and manufacturing services for small-molecule active pharmaceutical ingredients from pre-clinical to commercial manufacturing in the US. 

July 30th – ESTEVE acquires Regis Technologies, a United States-based Contract Development and Manufacturing Organization (CDMO), headquartered in Chicago.

This strategic move allows ESTEVE CDMO (actively operating under the Esteve Química brand) a physical presence in the United States, expanding its contract development and manufacturing solutions for innovative small-molecule active pharmaceutical ingredients (APIs) across the entire drug development lifecycle from pre-clinical to commercial manufacturing.

For over 65 years, Regis Technologies has been a US-based API CDMO, offering a broad spectrum of services, including process research & development, analytical & stability, cGMP API manufacturing, CMC support, and a variety of chromatography products.

“We are proud to strengthen our CDMO solutions for pharmaceutical innovators through this acquisition, while welcoming around 70 skilled professionals to our US team”, said Joan Petit, Chief Industrial Operations Officer of ESTEVE and General Manager of Esteve CDMO (Esteve Química).

Andrea Oro, Global Head of Commercial Operations and Strategy, added, “This acquisition enhances our early-stage development capabilities, and expands our global manufacturing footprint, allowing us to have an integrated service offering to better respond to our customers’ needs.”

“We are happy to join a company that shares our same values, a company that is also family-owned, with more than 90 years of experience, that is committed to people and focused on delivering long-term value to customers,” added Scott Aladeen, President and CEO of Regis Technologies.

ESTEVE CDMO (Esteve Química) is a global pure-play third-party CDMO, specializing in high-quality small-molecule active pharmaceutical ingredients and pharmaceutical intermediates, providing technologies such as Spray Drying and high-potency APIs (HPAPIs) manufacturing.

RBC Capital Markets served as financial advisor for ESTEVE, and Wombat Capital Markets served as financial advisor for Regis Technologies, for this operation.

 

About ESTEVE

ESTEVE (www.esteve.com) is a global pharmaceutical company with a clear purpose: to improve people’s lives. Founded in 1929 and headquartered in Barcelona, ESTEVE has a strong international presence with pharmaceutical affiliates in Spain, Portugal, Italy, Germany, France, the UK, and the USA.

ESTEVE is focused on delivering highly specialized treatments that address significant unmet medical needs in several therapeutic areas. In addition, to our innovative pharma business, we offer comprehensive Contract Manufacturing and Development services (CDMO), specializing in the production of Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, and China.

ESTEVE’s strong commitment to its core values—people matter, transparency, and accountability—remains at the heart of everything it does.

 

About Regis Technologies

Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support your discovery, lead molecule development and drug commercialization – from process development and analytical development, to stability services and cGMP API manufacturing. Our facilities are routinely inspected by the FDA and other global regulatory authorities. With our extensive organic chemistry & separations expertise, Regis also manufactures an innovative line of proprietary chromatography products sold throughout the world. Founded in 1956 by Dr. Louis Glunz III in Chicago, Regis is privately owned and operated.

 

For more information: 

Irene Simón, Head of Global External Communications & ESG, ESTEVE

Tel.+34 934 466 000 – isimon@esteve.com 

Gemma Mestre, External & Digital Communications Manager, ESTEVE

Tel.+34 934 466 000 – gmestre@esteve.com

 

Share

Information

  • Terms & Conditions
  • Site Map
  • Return Policy
  • Privacy Policy

About Us

  • About Regis
  • Services
  • Products
  • Upcoming Events

Contact Us

8210 Austin Ave
Morton Grove, IL 60053

+1(847) 967-6000
sales@registech.com

Find a Distributor

E-Mail Sign Up






     

     

    Website Created by Advanta Advertising, LLC.
    © 2025 Regis Technologies Inc. All Rights Reserved
    Contact Us
      0
      • Resources
      • Blog
      • News
      • Events
      • Careers

      [ Placeholder content for popup link ] WordPress Download Manager - Best Download Management Plugin

      The Regis Technologies Website is set to allow the use of cookies. Cookies help us to give you the best experience on our website. By clicking Accept or continuing to use the site, you agree to use our cookies. If you decline we will not track your information but your browsing experience might be limited. Please visit our Terms & Conditions and our Privacy Policy for more information.